Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
# If the Joomla site is installed within a folder such as at # e.g. www.example.com/joomla/ the robots.txt file MUST be # moved to the site root at e.g. www.example.com/robots.txt # AND the joomla folder name MUST be prefixed to the disallowed # path, e.g. the Disallow rule for the /administrator/ folder # MUST be changed to read Disallow: /joomla/administrator/ # # For more information about the robots.txt standard, see: # http://www.robotstxt.org/orig.html # # For syntax checking, see: # http://tool.motoricerca.info/robots-checker.phtml User-agent: * Disallow: /administrator/ Disallow: /bin/ Disallow: /cache/ Disallow: /cli/ Disallow: /components/ Disallow: /includes/ Disallow: /installation/ Disallow: /language/ Disallow: /layouts/ Disallow: /libraries/ Disallow: /logs/ Disallow: /modules/ Disallow: /plugins/ Disallow: /tmp/ |
Title | Apogenix ǀ Immuno-oncology therapeutics for the treatment of cancer and other malignant |
Description | Asunercept Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent |
Keywords | cancer, malignant diseases, oncology, oncological, hematology, hematological, protein therapeutics, APG101, glioblastoma, phase II trial, phase II study, efficacy, solid tumors, myelodysplastic syndromes, MDS, phase I trial |
WebSite | apogenix.com |
Host IP | 217.160.0.147 |
Location | Germany |
Site | Rank |
US$1,847,079
Last updated: 2022-06-30 21:28:38
apogenix.com has Semrush global rank of 5,730,294. apogenix.com has an estimated worth of US$ 1,847,079, based on its estimated Ads revenue. apogenix.com receives approximately 213,125 unique visitors each day. Its web server is located in Germany, with IP address 217.160.0.147. According to SiteAdvisor, apogenix.com is safe to visit. |
Purchase/Sale Value | US$1,847,079 |
Daily Ads Revenue | US$1,705 |
Monthly Ads Revenue | US$51,150 |
Yearly Ads Revenue | US$613,799 |
Daily Unique Visitors | 14,209 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
apogenix.com. | A | 3598 | IP: 217.160.0.147 |
apogenix.com. | NS | 86400 | NS Record: ns1037.ui-dns.de. |
apogenix.com. | NS | 86400 | NS Record: ns1037.ui-dns.biz. |
apogenix.com. | NS | 86400 | NS Record: ns1037.ui-dns.com. |
apogenix.com. | NS | 86400 | NS Record: ns1037.ui-dns.org. |
apogenix.com. | MX | 3600 | MX Record: 10 mx01.kundenserver.de. |
apogenix.com. | MX | 3600 | MX Record: 10 mx00.kundenserver.de. |
apogenix.com. | TXT | 3600 | TXT Record: MS=ms62829751 |
This website was not optimized for Internet Explorer 8 and cannot be displayed correctly. For optimal navigation, please upgrade your browser or open the website in a different browser. Home About Apogenix Company Profile Management Board Supervisory Board Investors Scientific Advisors Partnering Careers Immuno-Oncology Immuno-Oncology Overview TNF/TNFR Superfamily HERA-Ligand Technology Viral Infections Pipeline Pipeline Clinical Candidates Preclinical Candidates Scientific Publications Clinical Trials Glioblastoma Myelodysplastic Syndromes COVID-19 News & Events Press Releases Apogenix in the News Apogenix at Events Contact Contact Us Location & Directions DE EN Next Generation Immunotherapeutics Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF -dependent signaling pathways, thereby restoring the anti-tumor immune response in |
HTTP/1.1 301 Moved Permanently Content-Type: text/html; charset=utf-8 Connection: keep-alive Keep-Alive: timeout=15 Date: Wed, 27 Oct 2021 06:19:16 GMT Server: Apache P3P: CP="NOI ADM DEV PSAi COM NAV OUR OTRo STP IND DEM" Expires: Wed, 17 Aug 2005 00:00:00 GMT Cache-Control: no-store, no-cache, must-revalidate, post-check=0, pre-check=0 Pragma: no-cache Set-Cookie: 9dc5f294a8c67bdc1e1a950cefdf2ad3=c8df90283aaebcf40af5116f1882834d; path=/; secure; HttpOnly Location: https://apogenix.com/ Last-Modified: Wed, 27 Oct 2021 06:19:16 GMT HTTP/2 301 content-type: text/html; charset=utf-8 location: https://apogenix.com/en/ date: Wed, 27 Oct 2021 06:19:16 GMT server: Apache p3p: CP="NOI ADM DEV PSAi COM NAV OUR OTRo STP IND DEM" pragma: no-cache expires: Wed, 17 Aug 2005 00:00:00 GMT cache-control: no-store, no-cache, must-revalidate, post-check=0, pre-check=0, no-store, no-cache, must-revalidate, post-check=0, pre-check=0 set-cookie: 9dc5f294a8c67bdc1e1a950cefdf2ad3=6b4575bb8891b337c206814c48771028; path=/; secure; HttpOnly last-modified: Wed, 27 Oct 2021 06:19:16 GMT HTTP/2 200 content-type: text/html; charset=utf-8 date: Wed, 27 Oct 2021 06:19:17 GMT server: Apache p3p: CP="NOI ADM DEV PSAi COM NAV OUR OTRo STP IND DEM" expires: Wed, 17 Aug 2005 00:00:00 GMT cache-control: no-store, no-cache, must-revalidate, post-check=0, pre-check=0 pragma: no-cache set-cookie: 9dc5f294a8c67bdc1e1a950cefdf2ad3=c2f81d71af5f213b9f0a9e63fed13710; path=/; secure; HttpOnly last-modified: Wed, 27 Oct 2021 06:19:17 GMT |
Domain Name: APOGENIX.COM Registry Domain ID: 14294630_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.ionos.com Registrar URL: http://www.ionos.com Updated Date: 2020-12-01T08:24:35Z Creation Date: 1999-11-30T16:38:52Z Registry Expiry Date: 2021-11-30T16:38:52Z Registrar: 1&1 IONOS SE Registrar IANA ID: 83 Registrar Abuse Contact Email: abuse@ionos.com Registrar Abuse Contact Phone: +1.6105601459 Domain Status: ok https://icann.org/epp#ok Name Server: NS1037.UI-DNS.BIZ Name Server: NS1037.UI-DNS.COM Name Server: NS1037.UI-DNS.DE Name Server: NS1037.UI-DNS.ORG DNSSEC: unsigned >>> Last update of whois database: 2021-09-15T04:01:20Z <<< |